



**Cosentyx**<sup>®</sup>  
secukinumab

[Dermatology](#)

**Cosentyx<sup>®</sup> (secukinumab)**

[Prescribing information](#)




**Cosentyx**<sup>®</sup>  
secukinumab

Rheumatology

**Cosentyx<sup>®</sup> (secukinumab)**

[Prescribing information](#)



**FABHALTA**<sup>®</sup> ▼  
iptacopan

[Haematology](#)

**FABHALTA®▼ (iptacopan)**

[Prescribing information](#)



Haematology

**JAKAVI® (ruxolitinib)**

[Prescribing information](#)



Oncology

**KISQALI® (ribociclib)**

[Prescribing information](#)



Cardio-metabolic

**LEQVIO®▼ (inclisiran)**

[Prescribing information](#)



Oncology

**SANDOSTATIN® LAR® (octreotide acetate)**

[Prescribing information](#)



Haematology

**SCEMBLIX®▼ (asciminib)**

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/medicines>